Aarti Drugs Limited — PPTs, 03-02-2026: Investor Presentation

Here's a concise summary for Aarti Drugs Limited:

**1. Business Performance:**

Aarti Drugs reported steady Q3 FY26 results with total revenue up 8% YoY to ₹603 Crore. While EBITDA saw a 10% YoY dip to ₹56 Crore (margin 9.3%), Net Profit (PAT) surged 58% YoY to ₹41 Crore (margin 6.7%), boosted by a tax refund. For the nine-month period, revenue grew 8% to ₹1,847 Crore, and PAT increased 49% to ₹140 Crore. The API segment remains the largest contributor to revenue.

**2. Growth Drivers or Strategy:**

The company is actively operationalizing growth projects and focusing on backward integration. Its Sayakha plant for methyl amines is at 30% capacity, targeting 50% by March/April 2026, aiming for 100% self-reliance for Metformin in 6-8 months. The Salicylic Acid plant in Tarapur reached ~300 tonnes per month, reducing import dependence, with further downstream expansion planned.

**3. Recent Developments:**

Regulatory certifications and approvals are progressing as planned, including preparations for European approvals. Sales momentum is picking up, with encouraging traction observed in January, indicating a positive trend for coming quarters.

**4. Key Financial Metrics:**

Q3 FY26: Revenue +8% YoY, PAT +58% YoY, EBITDA -10% YoY. 9M FY26: Revenue +8% YoY, PAT +49% YoY, EBITDA +9% YoY. Earnings Per Share (EPS) for Q3 was ₹4.44.

**5. Management Commentary / Outlook:**

Management notes an inflection point with stable prices and increasing volumes after past realization pressure. The company is prioritizing operational efficiency, margin improvement, and capacity ramp-up while maintaining capital discipline.